, Ordre des médecins. Relation médecin
Prognosis of Patients With Stable Coronary Artery Disease (from the CORONOR Study), Am J Cardiol, vol.113, pp.1142-1145, 2014. ,
Effect of Beta-Blocker Dose on Survival After Acute Myocardial Infarction, J Am Coll Cardiol, vol.66, issue.13, pp.1431-1472, 2015. ,
BetaBlocker Therapy and Cardiac Events Among Patients With Newly Diagnosed Coronary Heart Disease, J Am Coll Cardiol, vol.64, issue.3, pp.247-52, 2014. ,
?-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease, JAMA, vol.308, issue.13, pp.1340-1349, 2012. ,
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials, Antithrombotic Trialists' (ATT) Collaboration, vol.373, pp.1849-60, 2009. ,
Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease, Eur Heart J, vol.21, issue.24, pp.2033-2074, 2000. ,
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes ,
, , vol.361, pp.1045-1057, 2009.
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial, Lancet Lond Engl, vol.373, issue.9665, pp.723-754, 2009. ,
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes, N Engl J Med, vol.350, issue.15, pp.1495-504, 2004. ,
Statines : des informations disponibles à la prescription courante, vol.35, pp.151-154, 2014. ,
, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet Lond Engl, vol.344, issue.8934, pp.1383-1392, 1994.
, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, Lancet Lond Engl, vol.360, issue.9326, pp.7-22, 2002.
Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med, vol.339, pp.1349-57, 2019. ,
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia, N Engl J Med, vol.333, issue.20, pp.1301-1309, 1995. ,
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevationThe Task Force for the management of acute myocardial infarction in patients presenting with STsegment elevation of the European Society of Cardiology (ESC), Eur Heart J, vol.00, pp.1-66, 2017. ,
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels ,
, N Engl J Med, vol.335, issue.14, pp.1001-1010, 1996.
, HAS. Guide du parcours de soin maladie coronarienne stable
Angiotensin-convertingenzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials, Lancet Lond Engl, vol.368, issue.9535, pp.581-589, 2006. ,
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients, Heart Outcomes Prevention Evaluation Study Investigators, vol.342, pp.145-53, 200020. ,
, Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). The Lancet, vol.362, pp.782-790, 2003.
,
, Angiotensin-converting-enzyme inhibition in stable coronary artery disease
, , vol.351, pp.2058-68, 2004.
Guide des 4000 médicaments utiles, inutiles ou dangereux. Le cherche midi, 2012. ,
One-year cardiovascular event rates in outpatients with atherothrombosis, JAMA, vol.297, pp.1197-206, 2007. ,
A prospective natural-history study of coronary atherosclerosis, N Engl J Med, vol.364, issue.3, p.38, 2011. ,
Rapport de l'académie de pharmacie. Observance des traitements médicamenteux en France, 2015. ,
Polypharmacy in the elderly: a literature review, J Am Acad.Nurse ? Pract, vol.17, issue.4, pp.123-132, 2005. ,
Polypharmacy in elderly patients, Am J Geriatr. Pharmacother, vol.5, issue.4, pp.345-351, 2007. ,
«La polymédication : définitions, mesures et enjeux Revue de la littérature et tests de mesure», 2014. ,
Données sur la mortalité en France : principales causes de décès en 2008 et évolutions depuis, Bull Epidémiol Hebd, issue.22, pp.249-55, 2000. ,
, , vol.17, p.476, 2014.
,
, Chaînage des données du PMSI avec les données de remboursement de l'assurance-maladie : exemple de l'analyse de la prévention secondaire après un infarctus du myocarde. Rev DÉpidémiologie Santé Publique, vol.57, p.87, 2009.
, Actes et prestations. Affections de longue durée. HAS, 2016.
, Haute Autorité de Santé Bonnes pratiques et criteres de qualite des revues et journaux de la presse medicale francaise. HAS, 2013.
Personnes hospitalisées pour infarctus du myocarde en France : tendances, Bull Epidémiol Hebd, issue.41, pp.459-65, 2002. ,
La maladie coronaire, session commune caisse nationale d'assurance maladie/SFC : les bases de données de l'assurance maladie : une mine d'or ? », congres SFC, vol.16, 2014. ,
Rien n'est permanent sauf le changement ,
Adherence to medication, N Engl J Med, vol.353, pp.487-497, 2005. ,
Thinking outside the pillbox -Medication adherence as a priority for health care reform, N Engl J Med, vol.362, pp.1553-1555, 2010. ,
Potentially inappropriate prescribing and cost outcomes for older people: a national population study, Br J Clin Pharmacol?, vol.69, issue.5, pp.543-552, 2010. ,
Rapport de la Commission nationale permanente adopté lors des Assises du Conseil national de l'Ordre des médecins du 19 juin, 2010. ,
,
, Cohorte EOLE en post-infarctus du myocarde : impact de la non-réponse aux questionnaires de suivi attendus sur le risque de mortalité à 6 ans, p.8
, Colloque Données de Santé en vie réelle, 2016.
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease ,
URL : https://hal.archives-ouvertes.fr/hal-01896445
, N Engl J Med, vol.376, issue.18, pp.1713-1735, 201704.
Cardiovascular risk in postmyocardial infarction patients: nationwide real world data demonstrate the ! 40 importance of a long-term perspective, Eur Heart J, vol.14, issue.19, pp.31357-31362, 2015. ,
Impact of a public media event on the use of statins in the French population, Archives of Cardiovascular Diseases ,
Evaluation of the impact of the recentcontroversy over statins in France: The EVANS study Évaluation de l'impact de la controverse récente sur les statines en France. Archives of cardiovascular Disease, 2013. ,
L'émergence d'un tiers public dans la relation médecin-malade: exemple du VIH. Science sociale et santé. 2000 mars, pp.76-119 ,